• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

    2/14/24 9:21:37 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    SC 13G/A 1 p24-0151sc13ga.htm MADRIGAL PHARMACEUTICALS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Madrigal Pharmaceuticals, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    558868105

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    þ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 55886810513G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Avoro Capital Advisors LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (see Item 4)*

    12

    TYPE OF REPORTING PERSON

    OO, IA

             

     

    * As more fully described in Item 4, the Warrants (as defined below) are subject to the 9.99% Blocker (as defined below) and the percentage set forth in row (11) gives effect to such blocker. However, rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).

     

    CUSIP No. 55886810513G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Behzad Aghazadeh

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,288,888 (including 400,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (see Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to the 9.99% Blocker and the percentage set forth in row (11) gives effect to such blocker. However, rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).

     

    CUSIP No. 55886810513G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      Madrigal Pharmaceuticals, Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
     

    Four Tower Bridge, 200 Barr Harbor Drive, Suite 200

    West Conshohocken, Pennsylvania 19428

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with Avoro, the “Reporting Persons”), who serves as the portfolio manager and controlling person of Avoro.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

     

    Item 2(c). CITIZENSHIP:
       
      Avoro is a Delaware limited liability company.  Dr. Aghazadeh is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER:
       
      558868105

     

     

    CUSIP No. 55886810513G/APage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.
       
      The percentage set forth in Row 11 of this Schedule 13G/A is calculated based upon 19,742,646 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 6, 2023 and assumes the exercise of certain warrants (the “Warrants”) to purchase Common Stock of the Company held by Avoro Life Sciences Fund LLC subject to the 9.99% Blocker
       
      Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the “9.99% Blocker”) and the percentage set forth in Row (11) of the cover page for each Reporting Person gives effect to the 9.99% Blocker.  Consequently, at this time, the Reporting Persons are not able to exercise all of such Warrants due to the 9.99% Blocker.  

     

     

    CUSIP No. 55886810513G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 55886810513G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE:  February 14, 2024  
       
    AVORO CAPITAL ADVISORS LLC  
       
       
    /s/ Scott Epstein  
    Name: Scott Epstein  
      Title:

    Chief Financial Officer &

    Chief Compliance Officer

     
       

    /s/ Behzad Aghazadeh

     
    BEHZAD AGHAZADEH  

     

     

     

    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings